Henry Schein Dirección

Dirección controles de criterios 3/4

El CEO de Henry Schein's es Stan Bergman , nombrado en Jan 1989, tiene una permanencia de 35.25 años. compensación anual total es $10.01M, compuesta por 16.2% salario y 83.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.38% de las acciones de la empresa, por valor de $35.47M. La antigüedad media del equipo directivo y de la junta directiva es de 8.3 años y 17.8 años, respectivamente.

Información clave

Stan Bergman

Chief Executive Officer (CEO)

US$10.0m

Compensación total

Porcentaje del salario del CEO	16.2%
Permanencia del CEO	35.3yrs
Participación del CEO	0.4%
Permanencia media de la dirección	8.3yrs
Promedio de permanencia en la Junta Directiva	17.8yrs

Actualizaciones recientes de la dirección

Recent updates

There Are Reasons To Feel Uneasy About Henry Schein's (NASDAQ:HSIC) Returns On Capital

Apr 14

Is There An Opportunity With Henry Schein, Inc.'s (NASDAQ:HSIC) 49% Undervaluation?

Aug 21

Henry Schein (NASDAQ:HSIC) Might Be Having Difficulty Using Its Capital Effectively

Aug 01

These 4 Measures Indicate That Henry Schein (NASDAQ:HSIC) Is Using Debt Reasonably Well

Jul 09

At US$74.94, Is Henry Schein, Inc. (NASDAQ:HSIC) Worth Looking At Closely?

Jun 09

Are Investors Undervaluing Henry Schein, Inc. (NASDAQ:HSIC) By 36%?

May 21

Henry Schein (NASDAQ:HSIC) Hasn't Managed To Accelerate Its Returns

May 01

Here's Why Henry Schein (NASDAQ:HSIC) Can Manage Its Debt Responsibly

Apr 10

Estimating The Intrinsic Value Of Henry Schein, Inc. (NASDAQ:HSIC)

Feb 15

Returns On Capital At Henry Schein (NASDAQ:HSIC) Have Stalled

Jan 28

These 4 Measures Indicate That Henry Schein (NASDAQ:HSIC) Is Using Debt Reasonably Well

Jan 10

Is There Now An Opportunity In Henry Schein, Inc. (NASDAQ:HSIC)?

Dec 11

Is There An Opportunity With Henry Schein, Inc.'s (NASDAQ:HSIC) 43% Undervaluation?

Nov 04

Buy Henry Schein To Receive 'Resiliency Premium' In Equity Portfolios

Aug 25

Henry Schein announces $400M increase to stock buyback plan

Aug 18

If EPS Growth Is Important To You, Henry Schein (NASDAQ:HSIC) Presents An Opportunity

Aug 09

Henry Schein Q2 2022 Earnings Preview

Aug 01

Be Wary Of Henry Schein (NASDAQ:HSIC) And Its Returns On Capital

Jul 04

Does Henry Schein (NASDAQ:HSIC) Have A Healthy Balance Sheet?

Jun 14

Henry Schein: Neutral On Valuation, Covid-19 Sales Slowdown

Jun 09

Henry Schein, Inc. (NASDAQ:HSIC) Shares Could Be 45% Below Their Intrinsic Value Estimate

May 27

Does Henry Schein (NASDAQ:HSIC) Deserve A Spot On Your Watchlist?

May 10

Investors Could Be Concerned With Henry Schein's (NASDAQ:HSIC) Returns On Capital

Apr 04

Henry Schein: A Great Play On Medical And Dental Products Trading At An Attractive Price

Mar 07

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Stan Bergman en comparación con los beneficios de Henry Schein?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 30 2023	US$10m	US$2m	US$416m
Sep 30 2023	n/a	n/a	US$445m
Jul 01 2023	n/a	n/a	US$458m
Apr 01 2023	n/a	n/a	US$478m
Dec 31 2022	US$8m	US$2m	US$538m
Sep 24 2022	n/a	n/a	US$638m
Jun 25 2022	n/a	n/a	US$650m
Mar 26 2022	n/a	n/a	US$646m
Dec 25 2021	US$11m	US$2m	US$631m
Sep 25 2021	n/a	n/a	US$626m
Jun 26 2021	n/a	n/a	US$606m
Mar 27 2021	n/a	n/a	US$438m
Dec 26 2020	US$6m	US$751k	US$403m
Sep 26 2020	n/a	n/a	US$591m
Jun 27 2020	n/a	n/a	US$585m
Mar 28 2020	n/a	n/a	US$713m
Dec 28 2019	US$14m	US$1m	US$701m
Sep 28 2019	n/a	n/a	US$488m
Jun 29 2019	n/a	n/a	US$444m
Mar 30 2019	n/a	n/a	US$438m
Dec 29 2018	n/a	n/a	US$431m
Sep 29 2018	n/a	n/a	US$304m
Jun 30 2018	n/a	n/a	US$352m
Mar 31 2018	n/a	n/a	US$377m

Compensación vs. Mercado: La compensación total ($USD10.01M) de Stan está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD8.28M).

Compensación vs. Ingresos: La compensación de Stan ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Stan Bergman (73 yo)

35.3yrs

Permanencia

US$10,005,729

Compensación

Mr. Stanley M. Bergman, also known as Stan, has been the Chief Executive Officer and Executive Chairman of Henry Schein, Inc. since 1989 and has been its Executive Director since 1982. Mr. Bergman served a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stanley Bergman	Executive Chairman & CEO	35.3yrs	US$10.01m	0.38% $ 33.7m
James Breslawski	Executive Vice Chairman & President	32.3yrs	US$2.69m	0.11% $ 9.9m
Ronald South	Senior VP & CFO	2.1yrs	US$2.35m	0.0077% $ 689.1k
Michael Ettinger	Executive VP & COO	1.8yrs	US$2.97m	0.019% $ 1.7m
Steven Paladino	Executive Director	2.1yrs	US$265.00k	0.095% $ 8.4m
Mark Mlotek	Executive VP	12.3yrs	US$3.22m	0.011% $ 1.0m
Olga Timoshkina	VP of Corporate Finance	2.7yrs	sin datos	sin datos
Christopher Pendergast	Senior VP & CTO	6.1yrs	sin datos	sin datos
Graham Stanley	VP of Investor Relations & Strategic Finance Project Officer	no data	sin datos	sin datos
Walter Siegel	Senior VP & Chief Legal Officer	10.6yrs	sin datos	0.034% $ 3.0m
Ann Gothard	Vice President of Global Corporate Media Relations	no data	sin datos	sin datos
Lorelei McGlynn	Senior VP & Chief Human Resources Officer	11yrs	sin datos	0.073% $ 6.5m

8.3yrs

Permanencia media

63yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de HSIC es experimentado (8.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Stanley Bergman	Executive Chairman & CEO	42.3yrs	US$10.01m	0.38% $ 33.7m
James Breslawski	Executive Vice Chairman & President	32.3yrs	US$2.69m	0.11% $ 9.9m
Steven Paladino	Executive Director	31.4yrs	US$265.00k	0.095% $ 8.4m
Mark Mlotek	Executive VP	28.7yrs	US$3.22m	0.011% $ 1.0m
Philip Laskawy	Independent Lead Director	22.3yrs	US$335.40k	0.029% $ 2.5m
Joseph Herring	Independent Director	8yrs	US$313.00k	0.017% $ 1.5m
Louis Sullivan	Chairman of Medical Advisory Board	17.8yrs	US$255.40k	sin datos
Norman Matthews	Member of Medical Advisory Board	no data	US$267.90k	sin datos
Bradley Sheares	Independent Director	14.3yrs	US$304.20k	0.0026% $ 231.5k
Carol Raphael	Independent Director	11.8yrs	US$282.60k	0.023% $ 2.0m
Kurt Kuehn	Independent Director	8yrs	US$316.40k	0.0014% $ 122.0k
Deborah Derby	Independent Director	3.3yrs	US$304.80k	0.00059% $ 52.5k

17.8yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de HSIC son experimentados ( 17.8 años antigüedad media).

Henry Schein Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Henry Schein, Inc. Announces Appointment of Members to the Company’S Executive Management Committee

Insider recently sold US$478k worth of stock

Henry Schein, Inc., Annual General Meeting, May 21, 2024

Henry Schein Appoints Carole T. Faig as New Independent Director

Insider recently sold US$835k worth of stock

Executive Vice Chairman & President notifies of intention to sell stock

Recent updates

There Are Reasons To Feel Uneasy About Henry Schein's (NASDAQ:HSIC) Returns On Capital

Henry Schein, Inc. to Report Q1, 2024 Results on May 07, 2024

Henry Schein, Inc. Announces Appointment of Members to the Company’S Executive Management Committee

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority interest in TriMed, Inc.

Insider recently sold US$478k worth of stock

Henry Schein, Inc., Annual General Meeting, May 21, 2024

Despite Disappointing Results, Henry Schein Looks Appealing Moving Forward

Full year 2023 earnings: EPS misses analyst expectations

Henry Schein, Inc. Presents Comprehensive Lineup of Solutions At the 2024 Chicago Dental Society Mid Winter Meeting

Henry Schein, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire an unknown majority interest in TriMed, Inc.

Henry Schein Appoints Carole T. Faig as New Independent Director

Henry Schein Announces Receipt of Deficiency Notice From Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

Henry Schein Announces Receipt of Deficiency Notice From Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

Henry Schein, Inc. Provides Earnings Guidance for 2023

Henry Schein, Inc. announced delayed 10-Q filing

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority stake in Shield HealthCare, Inc.

Is Henry Schein (NASDAQ:HSIC) A Risky Investment?

Is There Now An Opportunity In Henry Schein, Inc. (NASDAQ:HSIC)?

Is There An Opportunity With Henry Schein, Inc.'s (NASDAQ:HSIC) 49% Undervaluation?

Henry Schein, Inc. Affirms Earnings Guidance for the Full Year of 2023

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS misses analyst expectations

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire a majority stake in Shield HealthCare, Inc.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired a majority stake in Large Practice Sales LLC.

Henry Schein (NASDAQ:HSIC) Might Be Having Difficulty Using Its Capital Effectively

Henry Schein, Inc. to Report Q2, 2023 Results on Aug 07, 2023

These 4 Measures Indicate That Henry Schein (NASDAQ:HSIC) Is Using Debt Reasonably Well

Insider recently sold US$835k worth of stock

At US$74.94, Is Henry Schein, Inc. (NASDAQ:HSIC) Worth Looking At Closely?

Executive Vice Chairman & President notifies of intention to sell stock

Executive VP & COO notifies of intention to sell stock

Executive VP recently sold US$1.9m worth of stock

Executive VP notifies of intention to sell stock

Are Investors Undervaluing Henry Schein, Inc. (NASDAQ:HSIC) By 36%?

Henry Schein, Inc. Provides Sales Guidance for the Fiscal Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) agreed to acquire SIN - Sistema de Implante Nacional S.A. from Southern Cross Group.

Henry Schein (NASDAQ:HSIC) Hasn't Managed To Accelerate Its Returns

Here's Why Henry Schein (NASDAQ:HSIC) Can Manage Its Debt Responsibly

Independent Director recently sold US$148k worth of stock

Senior VP & Chief Legal Officer notifies of intention to sell stock

Independent Lead Director recently sold US$504k worth of stock

Independent Lead Director notifies of intention to sell stock

Independent Director recently sold US$923k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Henry Schein, Inc. Reports Impairment Charge on Intangible Assets for the Fourth Quarter Ended December 31, 2022

Now 25% undervalued

Estimating The Intrinsic Value Of Henry Schein, Inc. (NASDAQ:HSIC)

Henry Schein, Inc. (NasdaqGS:HSIC) announces an Equity Buyback for $400 million worth of its shares.

Returns On Capital At Henry Schein (NASDAQ:HSIC) Have Stalled

Henry Schein, Inc. to Report Q4, 2022 Results on Feb 16, 2023

These 4 Measures Indicate That Henry Schein (NASDAQ:HSIC) Is Using Debt Reasonably Well

Insider recently sold US$1.2m worth of stock

Now 21% undervalued

Is There Now An Opportunity In Henry Schein, Inc. (NASDAQ:HSIC)?

Is There An Opportunity With Henry Schein, Inc.'s (NASDAQ:HSIC) 43% Undervaluation?

Henry Schein, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Henry Schein, Inc. Announces its Lineup of Products and Solutions At the American Association of Oral and Maxillofacial Surgeons (AAOMS) Annual Conference in New Orleans, La. from September 12 Through September 17

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Midway Dental Supply, Inc.

Buy Henry Schein To Receive 'Resiliency Premium' In Equity Portfolios

Henry Schein announces $400M increase to stock buyback plan

Henry Schein, Inc. Announces the Passing of Board Member E. Dianne Rekow

If EPS Growth Is Important To You, Henry Schein (NASDAQ:HSIC) Presents An Opportunity

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Henry Schein, Inc. Affirms Earnings Guidance for the Full Year 2022

Henry Schein, Inc. Appoints Mark Hillebrandt as Chief Digital Revenue Officer